论文部分内容阅读
目的 了解癌基因ＣｅｒｂＢ２ 和Ｐ５３ 在良恶性肝病中的表达情况，分析其在肝细胞癌癌变过程中发生的作用．方法 用ｃＤＮＡｍ ＲＮＡ 原位杂交技术和免疫组化对２２ 例肝硬变，１１ 例癌前病变、即肝小细胞非典型增生，３５ 例肝癌及５ 例正常肝组织进行检测．结果 ＣｅｒｂＢ２ ｍ ＲＮＡ 的杂交阳性率在正常肝、肝小细胞非典型增生、肝硬变、分化较好肝癌组和分化较差肝癌组分别为０ ，７３ ％ ，６４ ％ ，３７ ％ 和２５ ％ ；ＣｅｒｂＢ２ 蛋白阳性率分别为０ ，１００ ％ ，８２ ％ ，４５ ％ 和２９ ％ ． Ｐ５３ ｍ ＲＮＡ 的杂交阳性率在正常肝、肝小细胞非典型增生（ＳＬＣＤ） 、肝硬变、分化较好肝癌组和分化较差肝癌组分别为０ ，７３ ％ ，６８ ％ ，３６ ％ 和２５ ％ ；Ｐ５３ 蛋白阳性率分别为０ ，０ ，０ ，２７ ％ 和４２ ％ ． 蛋白阳性物只见于肝癌细胞．结论 ＣｅｒｂＢ２ 癌基因可能在肝癌癌变的早期阶段起作用，主要作用于ＳＬＣＤ、胆管细胞、增生肝细胞． 野生型Ｐ５３ 有抗癌作用，突变型Ｐ５３ 致癌作用可能发生于肝癌癌变较晚阶段．
Objective To understand the expression of oncogene CerbB2 and P53 in benign and malignant liver diseases and to analyze their roles in the carcinogenesis of hepatocellular carcinoma. Methods Twenty-two cases of cirrhosis and 11 cases of precancerous lesions, ie, atypical hyperplasia of hepatocellular carcinoma, 35 cases of hepatocellular carcinoma and 5 cases of normal liver tissue were detected by cDNAmRNA in situ hybridization and immunohistochemistry. Results C erbB 2 m RNA hybridization positive rate in normal liver, small cell atypical hyperplasia, cirrhosis, well-differentiated liver cancer group and poorly differentiated liver cancer group were 0, 73%, 64%, 37% And 25%; C erbB 2 protein positive rates were 0, 100%, 82%, 45% and 29%. The positive rate of P53 m RNA hybridization was 0, 73%, 68%, 36% and 25 respectively in normal liver, atypical small cell dysplasia (SLCD), cirrhosis, poorly differentiated hepatocellular carcinoma and poorly differentiated hepatocellular carcinoma %; P53 protein positive rates were 0, 0, 0, 27% and 42%. Positive protein found only in liver cancer cells. Conclusion C erbB 2 oncogene may play an important role in the early stages of liver cancer carcinogenesis, the main role in the SLCD, cholangiocytes, proliferative liver cells. Wild-type P53 has anti-cancer effects, the mutation of P53 carcinogenesis may occur in the late stage of liver cancer.